Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial

US-based biotechnology company Sonnet BioTherapeutics has reported positive safety outcomes from a Phase Ib/IIa trial of high-dose SON-1010 (IL12-FHAB) in combination with Genentech’s atezolizumab in adults with advanced solid tumours or platinum-resistant ovarian cancer (PROC).